methyl-CpG binding domain protein 6Genealiases: []
Q-omics provides the consensus-scored MBD6 profile across patient tissues and cancer cell-line models. MBD6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MBD6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MBD6 RNA expression shows 20,092 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MBD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD6 survival associations across molecular data types. MBD6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD6 RNA expression–survival associations across cancer types. High MBD6 expression shows unfavorable associations in ACC, SKCM, LGG, HNSC and LIHC, but favorable associations in THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MBD6 RNA expression.
This table summarizes MBD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MBD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD6 shows higher tumor expression in KIRC, HNSC, LIHC, STAD, UCEC and BRCA. The KIRC box plot shows higher MBD6 RNA expression in tumor versus normal tissue (log2 FC = +0.644, t-test p < 0.001).
This table shows molecular features associated with MBD6 in patient tissues and cancer cell lines. In patient samples, MBD6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
